NEDAPLATIN

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C2H2O3.Pt.2H3N
Molecular Weight	303.181
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N.N.[Pt++].[O-]CC([O-])=O

InChI

InChIKey=GYAVMUDJCHAASE-UHFFFAOYSA-M

InChI=1S/C2H3O3.2H3N.Pt/c3-1-2(4)5;;;/h1H2,(H,4,5);2*1H3;/q-1;;;+2/p-1

HIDE SMILES / InChI

Molecular Formula	C2H2O3
Molecular Weight	74.0355
Charge	-2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H3N
Molecular Weight	17.0305
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Pt
Molecular Weight	195.084
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23696716
Curator's Comment: description was created based on several sources, including: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=36857 | https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=468844 | http://www.kegg.jp/medicus-bin/japic_med_product?id=00024597

Nedaplatin is a second-generation cisplatin analogue with antineoplastic activity. nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. It is currently registered for the treatment of various cancers (head and neck, testicular, lung, ovarian, cervical, non-small-cell lung) in Japan. The most commonly reported adverse reactions include nausea, vomiting, loss of appetite and hair loss. Nedaplatin may also cause nephrotoxicity at therapeutic doses, especially in patients with deteriorating renal function.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA 282 Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23696716	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Head and neck cancer 50 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=36857	Primary	Approved 8583	AQUPLA Approved Use Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer. Launch Date 1995
Small-cell lung cancer 41 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=36857	Primary	Approved 8583	AQUPLA Approved Use Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer. Launch Date 1995
Non-small cell lung cancer 211 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=36857	Primary	Approved 8583	AQUPLA Approved Use Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer. Launch Date 1995
Esophageal cancer 12 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=36857	Primary	Approved 8583	AQUPLA Approved Use Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer. Launch Date 1995
Bladder cancer 16 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=36857	Primary	Approved 8583	AQUPLA Approved Use Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer. Launch Date 1995
Testicular cancer 7 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=36857	Primary	Approved 8583	AQUPLA Approved Use Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer. Launch Date 1995
Ovarian cancer 160 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=36857	Primary	Approved 8583	AQUPLA Approved Use Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer. Launch Date 1995
Uterine cervix cancer 2 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=36857	Primary	Approved 8583	AQUPLA Approved Use Drug is usually used for the treatment of head and neck cancer, small cell lung cancer, non-small cell lung cancer, esophagus cancer, bladder cancer, testicular tumor, ovarian cancer and uterine cervix cancer. Launch Date 1995

C_max

Value	Dose	Co-administered	Analyte	Population
6.1 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/530169_4291405F1025_2_011_1F.pdf#page=27	80 mg/m² single, intravenous dose: 80 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		PLATINUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.34 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/530169_4291405F1025_2_011_1F.pdf#page=27	100 mg/m² single, intravenous dose: 100 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		PLATINUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.01 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16912889/	20 mg/m² single, intravenous dose: 20 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: PACLITAXEL	PACLITAXEL	PLATINUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
19.45 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/530169_4291405F1025_2_011_1F.pdf#page=27	80 mg/m² single, intravenous dose: 80 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		PLATINUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
30 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/530169_4291405F1025_2_011_1F.pdf#page=27	100 mg/m² single, intravenous dose: 100 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		PLATINUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.59 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16912889/	20 mg/m² single, intravenous dose: 20 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: PACLITAXEL	PACLITAXEL	PLATINUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.69 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/530169_4291405F1025_2_011_1F.pdf#page=27	80 mg/m² single, intravenous dose: 80 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		PLATINUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.3 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/530169_4291405F1025_2_011_1F.pdf#page=27	100 mg/m² single, intravenous dose: 100 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		PLATINUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16912889/	20 mg/m² single, intravenous dose: 20 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: PACLITAXEL	PACLITAXEL	PLATINUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
19% EXPERIMENT https://www.info.pmda.go.jp/go/interview/2/530169_4291405F1025_2_011_1F.pdf#page=28	100 mg/m² single, intravenous dose: 100 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered:		PLATINUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 100 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / 3 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/26831498/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/26831498/	DLT: Febrile neutropenia, Neutropenia... Dose limiting toxicities: Febrile neutropenia (grade 3, 25%) Neutropenia (grade 4, 25%) Sources: https://pubmed.ncbi.nlm.nih.gov/26831498/
160 mg/m2 1 times / 4 weeks multiple, intravenous MTD Dose: 160 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 160 mg/m2, 1 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/12477999/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/12477999/	DLT: Leukopenia, Thrombocytopenia... Dose limiting toxicities: Leukopenia (grade 4, 33.3%) Thrombocytopenia (grade 4, 16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/12477999/
90 mg/m2 1 times / 4 weeks multiple, intravenous MTD Dose: 90 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 90 mg/m2, 1 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/16821599/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16821599/	DLT: Neutropenia, Thrombocytopenia... Dose limiting toxicities: Neutropenia (grade 4, 33.3%) Thrombocytopenia (grade 4, 33.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/16821599/
90 mg/m2 1 times / 3 weeks multiple, intravenous RP2D Dose: 90 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 90 mg/m2, 1 times / 3 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/26831498/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/26831498/	Sources: https://pubmed.ncbi.nlm.nih.gov/26831498/

AEs

AE	Significance	Dose	Population
Febrile neutropenia	grade 3, 25% DLT	100 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 100 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / 3 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/26831498/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/26831498/
Neutropenia	grade 4, 25% DLT	100 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 100 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 100 mg/m2, 1 times / 3 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/26831498/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/26831498/
Thrombocytopenia	grade 4, 16.7% DLT	160 mg/m2 1 times / 4 weeks multiple, intravenous MTD Dose: 160 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 160 mg/m2, 1 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/12477999/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/12477999/
Leukopenia	grade 4, 33.3% DLT	160 mg/m2 1 times / 4 weeks multiple, intravenous MTD Dose: 160 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 160 mg/m2, 1 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/12477999/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/12477999/
Neutropenia	grade 4, 33.3% DLT	90 mg/m2 1 times / 4 weeks multiple, intravenous MTD Dose: 90 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 90 mg/m2, 1 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/16821599/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16821599/
Thrombocytopenia	grade 4, 33.3% DLT	90 mg/m2 1 times / 4 weeks multiple, intravenous MTD Dose: 90 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 90 mg/m2, 1 times / 4 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/16821599/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16821599/

PubMed

Title	Date	PubMed
[A case of SIADH developed during neoadjuvant chemotherapy using nedaplatin and 5-fluorouracil in a patient with esophageal cancer].	2010-09	20841948
[Nadaplatin or cisplatin combined with paclitaxol in treatment for non-small cell lung cancer: a randomized controlled study].	2007-06	17974278
Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors.	2007-06	17593098
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.	2006-11	16463059

Patents

Sample Use Guides

In Vivo Use Guide

Once daily over 60 minutes or longer, and then it is discontinued for at least 4 weeks. This dosing schedule as 1 course is repeated.

Route of Administration: Intravenous

In Vitro Use Guide

Nedaplatin inhibited the proliferation of SBC-3 cells by 98%, 93%, 75%, 54%, 27%, 6%, and 2% at a concentration of 0.005, 0.01, 0.025, 0.05, 0.1, 0.25, and 0.5 ug/ml, respectively. Consequently, its IC50 value for growth inhibition of SBC-3 cells was 0.053 ug/ml.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:13:36 GMT 2025` Edited by `admin` on `Mon Mar 31 18:13:36 GMT 2025`
Record UNII	8UQ3W6JXAN
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AQUPLA

Preferred Name

English

NEDAPLATIN

Official Name

English

NSC-375101D

Code

English

nedaplatin [INN]

Common Name

English

CIS-DIAMMINE(GLYCOLATO-O(SUP 1),O(SUP 2))PLATINUM

Common Name

English

CIS-DIAMMINE-GLYCOLATOPLATINUM

Common Name

English

CDGP

Common Name

English

NEDAPLATIN [JAN]

Common Name

English

Nedaplatin [WHO-DD]

Common Name

English

NEDAPLATIN [MART.]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

753320